Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Accenture
Colorcon
Fuji
Chubb
McKinsey
Farmers Insurance
Daiichi Sankyo
Cantor Fitzgerald
Novartis

Generated: December 11, 2017

DrugPatentWatch Database Preview

Brivaracetam - Generic Drug Details

« Back to Dashboard

What are the generic sources for brivaracetam and what is the scope of brivaracetam freedom to operate?

Brivaracetam
is the generic ingredient in one branded drug marketed by Ucb Inc and is included in three NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Brivaracetam has one hundred and forty-four patent family members in forty-one countries and six supplementary protection certificates in five countries.

One supplier is listed for this compound.

Summary for brivaracetam

Pharmacology for brivaracetam

Mechanism of ActionEpoxide Hydrolase Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Ucb IncBRIVIACTbrivaracetamTABLET;ORAL205836-003May 12, 2016RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Ucb IncBRIVIACTbrivaracetamTABLET;ORAL205836-005May 12, 2016RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Ucb IncBRIVIACTbrivaracetamTABLET;ORAL205836-001May 12, 2016RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Ucb IncBRIVIACTbrivaracetamTABLET;ORAL205836-002May 12, 2016RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Ucb IncBRIVIACTbrivaracetamSOLUTION;INTRAVENOUS205837-001May 12, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Ucb IncBRIVIACTbrivaracetamTABLET;ORAL205836-002May 12, 2016RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Ucb IncBRIVIACTbrivaracetamTABLET;ORAL205836-005May 12, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Ucb IncBRIVIACTbrivaracetamSOLUTION;ORAL205838-001May 12, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Ucb IncBRIVIACTbrivaracetamTABLET;ORAL205836-003May 12, 2016RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Ucb IncBRIVIACTbrivaracetamTABLET;ORAL205836-003May 12, 2016RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: brivaracetam

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,692,0282-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses► Subscribe
6,713,635 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
8,034,9582-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses► Subscribe
7,358,2762-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses► Subscribe
6,969,770 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
7,217,8262-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
6,858,740 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
6,806,287 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: brivaracetam

Country Document Number Estimated Expiration
Bulgaria65923► Subscribe
Japan2007182459► Subscribe
Yugoslavia63202► Subscribe
Poland212197► Subscribe
MexicoPA02008056► Subscribe
Poland365159► Subscribe
Hungary229514► Subscribe
Japan4769756► Subscribe
Norway20023997► Subscribe
China1740151► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: BRIVARACETAM

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016013Lithuania► SubscribePRODUCT NAME: BRIVARACETAMAS; REGISTRATION NO/DATE: EU/1/15/1073 20160114
90009-4Sweden► SubscribePRODUCT NAME: BRIVARACETAM; REG. NO/DATE: EU/1/15/1073 20150114
2016 00013Denmark► SubscribePRODUCT NAME: BRIVARACETAM; REG. NO/DATE: EU/1/15/1073/001-022 20160118
2016013,C1265862Lithuania► SubscribePRODUCT NAME: BRIVARACETAMAS; REGISTRATION NO/DATE: EU/1/15/1073 20160114
0815Netherlands► SubscribePRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 20160118
C1001France► SubscribePRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 20160118
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Express Scripts
Fuji
Medtronic
Boehringer Ingelheim
Argus Health
AstraZeneca
Federal Trade Commission
Covington
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot